At least, do no harm

Harold O Douglass Jr^{1

2}

Affiliations

¹ Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York.
² Department of Surgery, State University of New York at Buffalo, Buffalo, New York.

Free article

Editorial

Harold O Douglass Jr. Cancer. 2017.

Free article

. 2017 Oct 1;123(19):3660-3661.

doi: 10.1002/cncr.30865. Epub 2017 Jun 29.

Harold O Douglass Jr^{1

2}

¹ Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York.
² Department of Surgery, State University of New York at Buffalo, Buffalo, New York.

No abstract available

Comment on

Cost effectiveness of regorafenib as second-line therapy for patients with advanced hepatocellular carcinoma.
Parikh ND, Singal AG, Hutton DW. Parikh ND, et al. Cancer. 2017 Oct 1;123(19):3725-3731. doi: 10.1002/cncr.30863. Epub 2017 Jun 29. Cancer. 2017. PMID: 28662266